Publications

Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece

Published on: Clinical Drug Investigation
Authors: George Gourzoulidis, Argyro Solakidi, Marina Psarra, Eleni Nikitopoulou, Charalampos Tzanetakos , ,

Abstract Background and Objective:Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal disease primarily involving the axial skeleton. In addition, ankylosing spondylitis is associated with increased morbidity and...

Read More

Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece

Published on: Expert Review of Pharmacoeconomics & Outcomes Research
Authors: George Gourzoulidis, Oresteia Zisimopoulou , Andrianos Liavas , Charalampos Tzanetakos, ,

Abstract Objectives: To evaluate the cost-effectiveness of lorlatinib compared to 1st generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2nd generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung...

Read More

Pediatric Quality of Life Inventory (PedsQL) 3.0 Duchenne Muscular Dystrophy module-Greek Translation: A Quality of Life tool in Duchenne Muscular Dystrophy

Published on: WSEAS Transactions on Biology and Biomedicine
Authors: Eleni Katsomiti, Catherine Kastanioti, Elisabeth Chroni, George Mavridoglou, Assimina Douka, Antigone Karras, George Gourzoulidis,

Abstract: Purpose: Duchenne Muscular Dystrophy (DMD) is a genetic disorder in boys’ early childhood that adversely affects the cardiac, respiratory, and skeletal muscle’s function and emotional and social functioning as aspects of health-related quality of life...

Read More

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece

Published on: Frontiers in Public Health
Authors: George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, Jeffrey Vietri, Charalampos Tzanetakos,

Abstract: Objective: Higher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent...

Read More

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants

Published on: Vaccines (Basel)
Authors: Sophie Warren, Myrto Barmpouni, Vasiliki Kossyvaki, George Gourzoulidis, Johnna Perdrizet,

Abstract: In June 2010, Greece introduced the 13-valent pneumococcal conjugate vaccine (PCV13) for pediatric vaccination and has since observed a large decrease in pneumococcal disease caused by these vaccine serotypes, yet the disease prevalence of non-vaccine...

Read More

Archive per Year